UAE and Saudi Arabia: Gateways to International Biopharma Markets
Biopharmaceutical companies like Sanofi, AbbVie, and Virax Biolabs are capitalizing on lucrative business opportunities in the Middle East, particularly in the United Arab Emirates (UAE) and Saudi Arabia. These countries have become attractive markets for cutting-edge therapies, driven by their growing populations with a rising incidence of chronic diseases such as diabetes and cardiovascular disorders.
The Middle East is rapidly emerging as a pivotal healthcare market, marked by an escalating demand for innovative healthcare solutions. This demand has been further amplified by the region's struggle to cope with the challenges posed by the COVID-19 pandemic. "After experiencing the difficulties brought about by the pandemic, there is now a greater need for advanced healthcare solutions in the Middle East," said Cameron Shaw, Chief Operating Officer of Virax Biolabs. In response to this demand, Virax Biolabs recently established its regional headquarters at Dubai Science Park in the UAE.